How many institutions held ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share in Q2 2025?

72 institutional investors reported ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share for Q2 2025. Use the holders table for investor-level position and value details.

Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO)

Q: What does CUSIP 98937L105 represent in this 13F holders report?

CUSIP 98937L105 is the security identifier for ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

CUSIP: 98937L105

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 63,278,585
Total 13F shares: 34,055,191
Share change: +1,589,258
Total reported value: $329,977,952
Price per share: $9.69
Number of holders: 72
Value change: +$15,611,752
Number of buys: 44
Number of sells: 16

Quarterly Holders Quick Answers

What is CUSIP 98937L105?
CUSIP 98937L105 identifies ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 98937L105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Top shareholders of ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Enavate Sciences GP, LLC	3/4/5 13F	10%+ Owner · Company	5.9% from 13F	3,761,359	$63,943,103	—	16 Sep 2024	3/4/5 13F
SR ONE CAPITAL MANAGEMENT, LP	13F	Company	7.8%	4,911,539	$38,801,158	—	31 Mar 2025	13F
FMR LLC	13F	Company	4.5%	2,852,371	$22,533,732	—	31 Mar 2025	13F
NEA Management Company, LLC	13F	Company	4.1%	2,613,948	$20,650,189	—	31 Mar 2025	13F
Novo Holdings A/S	13F	Company	3.5%	2,214,967	$17,498,239	—	31 Mar 2025	13F
Fairmount Funds Management LLC	13F	Company	3%	1,892,806	$14,953,167	—	31 Mar 2025	13F
NVP Associates, LLC	13F	Company	2.9%	1,838,482	$14,524,008	—	31 Mar 2025	13F
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	3/4/5	10%+ Owner	— class O/S missing	801,624	$13,627,608	—	16 Sep 2024	3/4/5
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.5%	1,562,942	$12,347,242	—	31 Mar 2025	13F
Vivo Capital, LLC	13F	Company	1.9%	1,183,260	$9,347,754	—	31 Mar 2025	13F
FEDERATED HERMES, INC.	13F	Company	1.8%	1,158,000	$9,148,200	—	31 Mar 2025	13F
ArrowMark Colorado Holdings LLC	13F	Company	1.7%	1,097,369	$8,669,215	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	1.6%	1,014,110	$8,011,469	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	1.5%	975,906	$7,709,657	—	31 Mar 2025	13F
Rock Springs Capital Management LP	13F	Company	1.4%	878,667	$6,941,469	—	31 Mar 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	1.4%	873,623	$6,901,622	—	31 Mar 2025	13F
Pivotal bioVenture Partners Investment Advisor LLC	13F	Company	1.2%	736,645	$5,819,496	—	31 Mar 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.82%	517,606	$4,090,000	—	31 Mar 2025	13F
Eversept Partners, LP	13F	Company	0.7%	445,588	$3,520,145	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.56%	357,156	$2,822,059	—	31 Mar 2025	13F
Catalio Capital Management, LP	13F	Company	0.47%	295,148	$2,331,670	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.42%	266,200	$2,102,980	—	31 Mar 2025	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	0.26%	164,035	$1,340,166	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.19%	120,238	$949,880	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.18%	116,140	$917,506	—	31 Mar 2025	13F
SUPERSTRING CAPITAL MANAGEMENT LP	13F	Company	0.18%	111,605	$881,680	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.12%	77,910	$615,490	—	31 Mar 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.07%	44,067	$348,129	—	31 Mar 2025	13F
Bank of New York Mellon Corp	13F	Company	0.06%	35,188	$277,986	—	31 Mar 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.05%	31,757	$251,000	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.05%	31,626	$249,845	—	31 Mar 2025	13F
ALPS ADVISORS INC	13F	Company	0.04%	28,132	$222,243	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.04%	25,298	$199,854	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.04%	23,957	$189,260	—	31 Mar 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.04%	22,990	$181,621	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.03%	20,765	$164,044	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.03%	18,637	$147,232	—	31 Mar 2025	13F
Birchview Capital, LP	13F	Company	0.03%	16,500	$130,350	—	31 Mar 2025	13F
BARCLAYS PLC	13F	Company	0.03%	16,160	$127,664	—	31 Mar 2025	13F
SEI INVESTMENTS CO	13F	Company	0.02%	11,956	$94,464	—	31 Mar 2025	13F
INTECH INVESTMENT MANAGEMENT LLC	13F	Company	0.02%	11,599	$91,632	—	31 Mar 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.02%	11,514	$90,955	—	31 Mar 2025	13F
STONERIDGE INVESTMENT PARTNERS LLC	13F	Company	0.02%	10,955	$87,000	—	31 Mar 2025	13F
CITIGROUP INC	13F	Company	0.02%	10,810	$85,399	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	10,579	$83,574	—	31 Mar 2025	13F
MetLife Investment Management, LLC	13F	Company	0.02%	10,087	$79,687	—	31 Mar 2025	13F
Ting Xiao	3/4/5	Director	— mixed-class rows	47,000 mixed-class rows	$77,600	—	07 Feb 2025	3/4/5
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.01%	8,986	$70,989	—	31 Mar 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	8,163	$64,488	—	31 Mar 2025	13F
Corebridge Financial, Inc.	13F	Company	0.01%	7,529	$59,479	—	31 Mar 2025	13F

Institutional Holders of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) as of Q2 2025

As of 30 Jun 2025, Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) was held by 72 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,055,191 shares. The largest 10 holders included SR One Capital Management, LP, ENAVATE SCIENCES GP, LLC, FMR LLC, NEA Management Company, LLC, NOVO HOLDINGS A/S, Fairmount Funds Management LLC, FEDERATED HERMES, INC., NVP ASSOCIATES, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., and Vivo Capital, LLC. This page lists 72 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.